Melior Pharmaceuticals company fact sheet

Introduction:
Melior Pharmaceuticals identifies and develops new uses for small molecule therapeutics. By applying the proprietary theraTRACE® drug repositioning platform, Melior can rapidly evaluate compounds across multiple therapeutic areas. Once a new indication is identified, Melior advances the drug through its own internal drug development program or with a strategic partner.

Headquarters:
Exton, Pennsylvania, USA

History:
Founded by Andrew Reaume and Michael Saporito in January 2005; seed funding obtained in February 2005; fully operational in June 2005.

President and CEO:
Andrew G. Reaume, PhD, MBA

Current Partners:
Pfizer Inc., Immune Control Inc., Cephalon Inc., PolyMedix Inc., High Q Foundation, Merck and Co., Marillion Pharmaceuticals, and Othera Pharmaceuticals Inc.

For additional information, contact:
Dr. Andrew G. Reaume
President and CEO, Co-Founder
(610) 280-0633

Back to top of page